Determination of the delivered dose of nanoparticles in the trachea-bronchial and alveolar regions of the lung

Particle dosimetry is a necessary step for the risk assessment especially with regard to toxicological effects of nanoparticles. In many cases, dosimetry is linked to exposure via the surface area of the nanoparticles. Due to interface dependent reactions of particles and the lung tissue poorly soluble particles (PSP) are particularly in the focus of interest. In recent years the measurement the geometric particle surface area concentration, GSA, in the air and determination of the lung deposited surface area (LDSA) based on lung deposition models gained interest. The effective particle concentration in the Lung (LDSA) cannot be measured directly. The maxima of many common airborne particle surface area distributions occur in the particle size range below 400 nm. High alveolar and trachea-bronchial deposition can be encountered in this size range.